Novozymes Biopharma has announced two new scientific posters to be presented at the 2011 Controlled Release Society (CRS) meeting and exposition, July 30–August 3, Maryland, USA. The posters highlight the formulation and stabilization capabilities of recombinant albumin (rAlbumin) to safeguard the integrity of protein drug substances as well as the potential for combining hyaluronic acid (HA) and diclofenac sodium to extend drug release in osteoarthritis applications.
The first poster, entitled ‘Recombinant Albumin: A multipurpose excipient for formulation and stabilization of biotherapeutics’, examines rAlbumin as an effective stabilizing excipient for 3D7 and FC27 malaria antigen proteins in liquid formulations. The findings demonstrate the potential of rAlbumin to safeguard proteins’ integrity preventing aggregation, oxidation and non-specific binding.
The second poster is entitled ‘Compatibility between diclofenac sodium and hyaluronic acid and release of diclofenac sodium from hyaluronic acid-containing preparations towards the treatment of osteoarthritis’.
The findings of the poster indicate that the addition of HA to diclofenac-containing commercial formulations can extend drug release from less than 15 minutes to 10 hours, offering new advances for future intra-articular preparations intended for the treatment of osteoarthritis.
For further information, www.biopharma.novozymes.com
The first poster, entitled ‘Recombinant Albumin: A multipurpose excipient for formulation and stabilization of biotherapeutics’, examines rAlbumin as an effective stabilizing excipient for 3D7 and FC27 malaria antigen proteins in liquid formulations. The findings demonstrate the potential of rAlbumin to safeguard proteins’ integrity preventing aggregation, oxidation and non-specific binding.
The second poster is entitled ‘Compatibility between diclofenac sodium and hyaluronic acid and release of diclofenac sodium from hyaluronic acid-containing preparations towards the treatment of osteoarthritis’.
The findings of the poster indicate that the addition of HA to diclofenac-containing commercial formulations can extend drug release from less than 15 minutes to 10 hours, offering new advances for future intra-articular preparations intended for the treatment of osteoarthritis.
For further information, www.biopharma.novozymes.com
